ID

43797

Descripción

Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors; ODM derived from: https://clinicaltrials.gov/show/NCT02352779

Link

https://clinicaltrials.gov/show/NCT02352779

Palabras clave

Versiones (2)
  1. 2/5/16 2/5/16 -
  2. 20/9/21 20/9/21 -
Subido en

20 de septiembre de 2021

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Breast Carcinoma NCT02352779

Inglés

Eligibility Breast Carcinoma NCT02352779

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
have a confirmed diagnosis of breast cancer; participants can have had more than one primary cancer diagnosis in the past
Descripción

Breast Carcinoma | Primary malignant neoplasm Past

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0678222
UMLS CUI [2,1]
C1306459
UMLS CUI [2,2]
C1444637
have undergone some type or combination of standard adjuvant treatment (surgery, chemotherapy, radiation therapy) for breast cancer
Descripción

Adjuvant therapy Breast Carcinoma | Operative Surgical Procedures | Chemotherapy Regimen | Therapeutic radiology procedure

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0677850
UMLS CUI [1,2]
C0678222
UMLS CUI [2]
C0543467
UMLS CUI [3]
C0392920
UMLS CUI [4]
C1522449
have completed all forms of standard adjuvant treatment (surgery, chemotherapy, radiation therapy) for breast cancer between 4 and 36 months prior to enrollment in the study; participants can be currently taking hormones (such as tamoxifen) or monoclonal antibodies (such as herceptin)
Descripción

Adjuvant therapy Breast Carcinoma completed | Operative Surgical Procedures | Chemotherapy Regimen | Therapeutic radiology procedure | Hormone preparation | Tamoxifen | Monoclonal antibodies, antineoplastic | Herceptin

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0677850
UMLS CUI [1,2]
C0678222
UMLS CUI [1,3]
C1556116
UMLS CUI [2]
C0543467
UMLS CUI [3]
C0392920
UMLS CUI [4]
C1522449
UMLS CUI [5]
C0019932
UMLS CUI [6]
C0039286
UMLS CUI [7]
C3542957
UMLS CUI [8]
C0338204
must have cancer-related fatigue, as indicated by a response of 4 or greater when asked to rate their level of fatigue at its worst in the past week on an 11-point scale anchored by "0" = no fatigue and "10" = as bad as you can imagine
Descripción

Fatigue Malignant Neoplasms | Level of fatigue

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0015672
UMLS CUI [1,2]
C0006826
UMLS CUI [2]
C2586108
be able to read english
Descripción

Able to read English Language

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0586740
UMLS CUI [1,2]
C0376245
able to swallow medication
Descripción

Able to swallow oral medication

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2712086
UMLS CUI [1,2]
C0175795
give written informed consent
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
have used marine omega-3 supplements at any time within previous 3 months (this includes prescription omega-3 drugs such as lovaza®)
Descripción

Omega-3 Fatty Acids | Pharmaceutical Preparations Lovaza

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0015689
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0912903
be taking anticoagulant medication (does not include aspirin)
Descripción

Anticoagulants | Aspirin

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0003280
UMLS CUI [2]
C0004057
have sensitivity or allergy to fish and/or shellfish
Descripción

Hypersensitivity Fishes | Hypersensitivity Shellfish

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0016163
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C1304606
have sensitivity or allergy to soy and/or soybeans
Descripción

Hypersensitivity Soy | Hypersensitivity Soybeans

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C2756587
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0037733
have confirmed diagnosis of chronic fatigue syndrome or other diagnosis known to cause severe fatigue
Descripción

Chronic Fatigue Syndrome | Diagnosis Causing Fatigue Severe

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0015674
UMLS CUI [2,1]
C0011900
UMLS CUI [2,2]
C0678227
UMLS CUI [2,3]
C0015672
UMLS CUI [2,4]
C0205082
Volver a la parte superior de la página

Similar models

Eligibility Breast Carcinoma NCT02352779

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Breast Carcinoma | Primary malignant neoplasm Past
Item
have a confirmed diagnosis of breast cancer; participants can have had more than one primary cancer diagnosis in the past
boolean
C0678222 (UMLS CUI [1])
C1306459 (UMLS CUI [2,1])
C1444637 (UMLS CUI [2,2])
Adjuvant therapy Breast Carcinoma | Operative Surgical Procedures | Chemotherapy Regimen | Therapeutic radiology procedure
Item
have undergone some type or combination of standard adjuvant treatment (surgery, chemotherapy, radiation therapy) for breast cancer
boolean
C0677850 (UMLS CUI [1,1])
C0678222 (UMLS CUI [1,2])
C0543467 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C1522449 (UMLS CUI [4])
Adjuvant therapy Breast Carcinoma completed | Operative Surgical Procedures | Chemotherapy Regimen | Therapeutic radiology procedure | Hormone preparation | Tamoxifen | Monoclonal antibodies, antineoplastic | Herceptin
Item
have completed all forms of standard adjuvant treatment (surgery, chemotherapy, radiation therapy) for breast cancer between 4 and 36 months prior to enrollment in the study; participants can be currently taking hormones (such as tamoxifen) or monoclonal antibodies (such as herceptin)
boolean
C0677850 (UMLS CUI [1,1])
C0678222 (UMLS CUI [1,2])
C1556116 (UMLS CUI [1,3])
C0543467 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C1522449 (UMLS CUI [4])
C0019932 (UMLS CUI [5])
C0039286 (UMLS CUI [6])
C3542957 (UMLS CUI [7])
C0338204 (UMLS CUI [8])
Fatigue Malignant Neoplasms | Level of fatigue
Item
must have cancer-related fatigue, as indicated by a response of 4 or greater when asked to rate their level of fatigue at its worst in the past week on an 11-point scale anchored by "0" = no fatigue and "10" = as bad as you can imagine
boolean
C0015672 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
C2586108 (UMLS CUI [2])
Able to read English Language
Item
be able to read english
boolean
C0586740 (UMLS CUI [1,1])
C0376245 (UMLS CUI [1,2])
Able to swallow oral medication
Item
able to swallow medication
boolean
C2712086 (UMLS CUI [1,1])
C0175795 (UMLS CUI [1,2])
Informed Consent
Item
give written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Omega-3 Fatty Acids | Pharmaceutical Preparations Lovaza
Item
have used marine omega-3 supplements at any time within previous 3 months (this includes prescription omega-3 drugs such as lovaza®)
boolean
C0015689 (UMLS CUI [1])
C0013227 (UMLS CUI [2,1])
C0912903 (UMLS CUI [2,2])
Anticoagulants | Aspirin
Item
be taking anticoagulant medication (does not include aspirin)
boolean
C0003280 (UMLS CUI [1])
C0004057 (UMLS CUI [2])
Hypersensitivity Fishes | Hypersensitivity Shellfish
Item
have sensitivity or allergy to fish and/or shellfish
boolean
C0020517 (UMLS CUI [1,1])
C0016163 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1304606 (UMLS CUI [2,2])
Hypersensitivity Soy | Hypersensitivity Soybeans
Item
have sensitivity or allergy to soy and/or soybeans
boolean
C0020517 (UMLS CUI [1,1])
C2756587 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0037733 (UMLS CUI [2,2])
Chronic Fatigue Syndrome | Diagnosis Causing Fatigue Severe
Item
have confirmed diagnosis of chronic fatigue syndrome or other diagnosis known to cause severe fatigue
boolean
C0015674 (UMLS CUI [1])
C0011900 (UMLS CUI [2,1])
C0678227 (UMLS CUI [2,2])
C0015672 (UMLS CUI [2,3])
C0205082 (UMLS CUI [2,4])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial